Water drawn from a living Equisetum plant, called horsetail, has registered the most extreme oxygen isotope signature ever measured.
Get the latest international news and world events from around the world.
The role of noradrenergic innervation and β-cell dedifferentiation in diabetes
Noradrenergic innervation and β-cell dedifferentiation in diabetes.
Dedifferentiation, a survival mechanism whereby mature β-cells revert to a nonfunctional state under metabolic stress, represents a fundamental driver of β-cell failure in type 2 diabetes.
Dedifferentiation is reversible, primarily through dietary intervention or bariatric surgery, and redifferentiation may promote type 2 diabetes remission.
Noradrenergic fiber density is increased in diabetic pancreases and correlates with β-cell dedifferentiation, suggesting that altered signaling may trigger the process.
A link between diet, redifferentiation, reduction of noradrenergic fibers, and type 2 diabetes remission has been hypothesized.
The review proposes that targeting pancreatic noradrenergic innervation could be a novel therapeutic strategy to reverse β-cell dedifferentiation, restore insulin function, and achieve type 2 diabetes remission. sciencenewshighlights ScienceMission https://sciencemission.com/noradrenergic-innervation–in-diabetes
Water-splitting catalyst unlocks cheaper hydrogen at significantly lower temperatures
University of Birmingham research published today has shown a new low-temperature method for producing hydrogen that is suitable for both centralized hydrogen production, and also local generation using waste heat from large-scale industrial plants.
Hydrogen is the most abundant element in the universe and is a clean and environmentally friendly energy carrier. Unlike fossil fuels, which produce harmful emissions and carbon dioxide, it produces only heat and water on combustion and can also power fuel cells that produce electricity. But while hydrogen is carbon-free at the point of use, 95% of current production relies on fossil fuels.
Thermochemical splitting, where a catalyst splits water into hydrogen and oxygen, is emerging as a promising method for hydrogen production. However, current catalysts split water at 700‑1000oC and need temperatures between 1,300 and 1500oC to regenerate between cycles of water-splitting.
Baicalein Alleviates Iron Overload-Induced Ferroptosis and Osteogenic Blockade in Osteoblasts by Activating the Nrf2/GPX4 Pathway
JUST PUBLISHED:Click here to read the latest free, Open Access article from BMEF.
The transcription factor Nrf2 orchestrates cellular defenses against redox imbalance and lipid peroxidation, partly through regulating the expression of 2 key gatekeepers of ferroptosis: SLC7A11 and GPX4 [44]. As such, the Keap1/Nrf2 pathway is recognized as a master regulator of ferroptosis in osteoblasts [45]. Under stress conditions, Nrf2 dissociates from the Keap1–Nrf2 complex, translocates into the nucleus, and initiates the transcription of genes containing antioxidant response elements [46]. Previous studies have reported that Nrf2 activation protects osteoblasts from ferroptosis in bone tissue and alleviates osteoporosis [28,47]. Consistently, we observed that under iron overload conditions, baicalein restored nuclear Nrf2 levels and the expression of downstream targets GPX4 and SLC7A11. Both genetic and pharmacological inhibition of Nrf2 abolished the cytoprotective and pro-osteogenic effects of baicalein. These findings suggest that baicalein prevents ferroptosis in osteoblasts via activation of the Nrf2/GPX4 pathway.
Clinically, iron overload conditions, such as transfusion-induced iron overload in thalassemia and hereditary hemochromatosis, are strongly associated with low bone mass and increased fracture risk [48,49]. Current treatment options (e.g., iron chelators, phlebotomy, and anti-resorptive agents) fail to simultaneously address iron overload and bone damage. Baicalein has undergone human safety and pharmacokinetic studies, which indicate no significant side effects even at high doses [50,51]. Our study demonstrates that baicalein not only prevents bone loss by protecting osteoblasts from ferroptosis but also effectively reduces systemic iron storage. Although beyond the scope of this work, baicalein’s known anti-osteoclastogenic effects may synergistically contribute to its overall bone-protective actions in iron overload conditions. These findings suggest that baicalein is a promising therapeutic agent for iron overload-related bone disorders. Although clinical trials are warranted, the dose of baicalein used in our study was extrapolated from clinically tolerated doses in humans, thereby supporting the potential feasibility of its clinical application.
In summary, this study provides the first definitive evidence that baicalein effectively inhibits iron overload-induced ferroptosis in osteoblasts by activating the Nrf2/GPX4 signaling pathway, thereby promoting bone formation and preventing bone loss. Our findings not only elucidate the mechanism by which baicalein functions as a novel ferroptosis inhibitor in bone protection but also highlight its role as a “dual-function” therapeutic strategy—combining iron chelation and anti-bone-loss capacities. Given its favorable safety profile and existing human pharmacokinetic data, our results provide strong preclinical evidence supporting the clinical translation of baicalein for the treatment of iron overload-related bone diseases. Targeting the ferroptosis pathway, particularly via Nrf2/GPX4 activation by baicalein, represents a highly promising novel strategy for preventing and treating iron overload-induced bone loss.
The first personalized brain repair for Parkinson’s
Parkinson’s disease has been a repetitive pattern of tremors, stiffness, slowing movement and an eventual dependence on medications that soften (but never stop) the decline. But what if that script is no longer fixed? What if the brain, instead of being carefully managed as it deteriorates, could actually be rebuilt from the patient’s own biology?
These questions are no longer purely theoretical. In early clinical data presented at the AD/PD 2026 International Conference in Copenhagen, San Diego-based biotech Aspen Neuroscience shared results suggesting an unusual finding in neurodegenerative disease: early signs of restoration [1]. Not slowing, not masking, but restoring.
At the center of Aspen’s approach is a radical idea of using the patient’s own cells as raw material to rebuild what Parkinson’s has taken away.
Understanding how lasers can rapidly magnetize fusion plasmas
The mechanism that can cause a rapidly expanding plasma—the superhot state of matter harnessed in fusion energy systems—to spontaneously generate its own magnetic fields was identified through a new set of simulations. This improves our understanding of naturally occurring plasmas in our universe and advances the development of fusion systems based on an approach called direct-drive inertial fusion.
In a direct-drive inertial fusion system, powerful lasers compress a small, fuel-filled capsule, heating it until fusion reactions occur. Unexpected magnetic fields can change how heat moves through the plasma in ways that existing simulation tools can miss. Accurate simulations are critical to designing fusion systems that will behave as expected and deliver net energy on a long-term basis.
In laboratory experiments, researchers found that high-powered lasers can vaporize a solid target in an instant, turning it into plasma that rapidly expands. Experiments have repeatedly detected very strong magnetic structures emerging from this expanding plasma, but the precise origin of these fields has long been a matter of debate.
Brain-based index may reveal Alzheimer’s risk patterns in adults as young as 30
Over the past few decades, neuroscientists and medical researchers worldwide have been trying to leverage available health records, brain scans and other medical data to uncover biological markers associated with the onset of specific diseases or neuropsychiatric disorders. The identification of these biomarkers could help to devise new tools to predict the risk that individual patients will develop a specific condition, allowing doctors to intervene early, preventing or delaying its emergence or slowing down its progression.
Researchers at the University of Texas Health Science Center, UTHealth Houston School of Behavioral Health Sciences, Keck School of Medicine of USC, and University of Maryland School of Medicine recently devised a new brain-based index that could be used to track early risk factors that, in specific people, may lead to the development of Alzheimer’s disease (AD). AD is a progressive neurodegenerative condition that prompts the deterioration and death of brain cells, leading to progressive memory loss and a decline in mental functions. AD has very limited treatment options after the diagnosis but the brain changes that culminate in AD take decades, thus suggesting that public effort should be focused on prevention.
The researchers devised an index that could be used to quantify patterns in a person’s brain that measure the similarity to those observed in individuals diagnosed with AD and followed as a part of the research studies such as Alzheimer’s Disease Neuroimaging Initiative (ADNI). This index, introduced in a paper published in Molecular Psychiatry, was derived by performing a mega-analysis of publicly available brain imaging data collected from people with and without AD.